Please use a PC Browser to access Register-Tadawul
Get It
VYNE Therapeutics shares are trading higher after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.
VYNE THERAPEUTICS INC VYNE | 2.41 | -0.41% |